Thought Leader Select’s Post

To learn more about our clinical trial, visit our website: https://lnkd.in/eAjYXywY. #JARofHope #SpreadHope #savethefirstchild #penniesforhope #duchennemusculardystrophy #searchforacure #musculardystrophy #DuchenneAwareness #BreakTheSilence #HopeForDMD

Learn how Calyx's #MedicalImaging team – the industry’s largest and most diverse/experienced group of scientific & medical experts – is future-focused to help #ClinicalTrial sponsors succeed. Meet them at upcoming industry events. https://lnkd.in/gMgW5pwU #ChooseCalyx #ClinicalTrials #ESMO2023 #CTAD23

#CTSS #Day1 Dr Sumeet Ambarkhane, MD, Shaantanu Donde, Cornelia Baumgartner- Diolaiuti, Elizabeth Eagling-Vose, MBA, Pauline Frank and Dr. Andriy K. discussed "Optimizing Clinical Development: Leveraging Integrated Medical Affairs and Streamlined Clinical Trial Processes" at #CTSS . . This insightful presentation took place on #Day1 of #CTSS2024! . Keep an eye out for further updates from hashtag #clinicaltrials #16thctss2024 #PharmaInnovation #UnlockPotential #summit2024 #staytunedformore.

To learn more about our clinical trial, visit our website: https://lnkd.in/eMTHs6nq. #JARofHope #SpreadHope #savethefirstchild #penniesforhope #duchennemusculardystrophy #searchforacure #musculardystrophy #DuchenneAwareness #BreakTheSilence #HopeForDMD

I recommend this EBAC accredited online seminar on Mon Oct 14th 2024 dealing with life-threatening hemorrhage associated with Direct Oral AntiCoagulants (DOACs). With the increasing use of these drugs in clinical practice, we in Emergency medicine need to familiar with managing their relatively infrequent but dreaded complication.

Learn how Calyx's #MedicalImaging team – the industry’s largest and most diverse/experienced group of scientific & medical experts – is future-focused to help #ClinicalTrial sponsors succeed. Meet them at upcoming industry events. https://lnkd.in/g-VY-wY5 #ChooseCalyx #ClinicalTrials #ESMO2023 #CTAD23

DynamX Bioadaptor demonstrates significant clinical advantages vs. DES. Learn more: https://bit.ly/3ULJe9l Join Elixir Medical at #EuroPCR 2024 to learn more about #Bioadaptor #DynamX Sponsored post by Elixir Medical Corporation

I am thrilled to announce the publication of a novel and comprehensive design known as the Gen 1-2-3 design, which encompasses all stages of clinical treatment evaluation. This innovative design stands out as one of the earliest seamless clinical trial design frameworks, seamlessly integrating the phase 1-2 dose optimization design with the phase 2-3 confirmatory treatment comparison design. The Gen 1-2-3 design incorporates the following key features: (1) utilizing phase 1-2 criteria to identify a set of candidate doses, (2) selecting the optimal dose based on survival outcomes, and (3) making a Go/No-Go decision regarding the continuation to phase 3 based on the predictive probability of the hazard ratio between the optimal dose and the control. https://lnkd.in/gG5kCSW9

Results from a phase 3 clinical trial provide new insights into management of patients with mCRPC 🩺    Abstract: LBA1, Proffered Paper     Discover more: https://lnkd.in/eytECTz8

𝗜𝗜𝗧𝘀: 𝗪𝗵𝗮𝘁’𝘀 𝘁𝗵𝗲 𝗕𝗶𝗴 𝗗𝗲𝗮𝗹?🔍 Swipe left to see how Investigator-Initiated Trials (IITs) are transforming medical research and making patient care better. 🎯 Prime example of how MONIPOL | Clinical Research is at the forefront of supporting IITs is the TherVacB project, read more: https://lnkd.in/d_teknV4